“Project Integrum” is a unique and innovative large-scale drug development initiative initiated by Biocytogen, which is built upon the human antibody platform RenMice (RenMab, RenLite, and RenNano) and their derived 6 six major technological platforms: fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (ADCs), nanobodies, TCR-mimic antibodies, and GPCR antibodies.

These platforms are utilized for the development of antibody-based drugs against 1000+ targets in various forms such as monoclonal antibodies, bispecific antibodies, nanobodies, ADCs, TCR-mimic antibodies, and cell therapies, catering to the enormous global medical demand.

With the formation of a rich diversity of high-quality antibody molecule library, the program is committed to achieving the goal of new drug development through technology innovations and open and cooperative attitude with global pharmaceutical companies.